Stocks Health care OTLK
NASDAQ · Health careOutlook Therapeutics, Inc. (OTLK)
It posted a net loss of $61.1M. At June 30, 2026 it held $11.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 18, 2026.
Key facts about Outlook Therapeutics, Inc.
- Net worth
- Outlook Therapeutics, Inc. has a market value (market cap) of $111.8M at the latest share price, and shareholders' equity of -$10.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.4M (-82.6% year on year), with a net loss of $62.4M.
- Cash flow
- In fiscal 2025 operations used $51.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 18, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Outlook Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Outlook Therapeutics, Inc. does
Outlook Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OTLK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4M | -$62.4M | -$1.79 | n/a |
| 2024 | n/a | -$75.4M | -$4.06 | n/a |
| 2023 | n/a | -$59M | -$4.72 | n/a |
| 2022 | n/a | -$66.1M | -$6.10 | n/a |
| 2021 | n/a | -$53.2M | -$6.88 | n/a |
| 2020 | n/a | -$35.2M | -$13.18 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OTLK ranks in Health care
Latest SEC filings
What Outlook Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026
- September 18, 2026Other event 8-K
- August 27, 2026
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 18, 2026
- August 17, 2026Late quarterly report notice NT 10-Q
- August 14, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Other event 8-K
- August 14, 2026
Insider trades
What the people running Outlook Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought shares on the open market in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 14, 2026 | Jahr Robert CharlesChief Executive Officer, Director | Bought | 151,515 | - |
| August 14, 2026 | Kenyon Lawrence AChief Financial Officer, Director | Bought | 101,010 | - |
| August 12, 2026 | Sukhtian Ghiath M.Director, 10% owner | Boughtindirect | 2,525,252 | $2.5M |
| July 29, 2026 | Sukhtian Faisal GhiathDirector | Bought | 95,398 | $100K |
| June 2, 2026 | Haddadin Yezan MuntherDirector | Bought | 29,000 | $24.1K |
| May 28, 2026 | Sukhtian Ghiath M.Director, 10% owner | Boughtindirect | 8,539,709 | $5M |
| May 27, 2026 | Sukhtian Faisal GhiathDirector | Bought | 122,174 | $50K |
| May 26, 2026 | Hilzinger Kurt JDirector | Bought | 400,000 | $176.5K |
Who owns OTLK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| GMS Ventures & Investments13D, may seek influence with 1 related filers | 16.4% | August 14, 2026 |
| Syntone Ventures LLC13D, may seek influence with 2 related filers | 11.4% | April 17, 2024 |
| CVI Investments, Inc.13G, passive with 1 related filers | 9.9% | August 19, 2026 |
| Empery Asset Management, LP13G, passive with 1 related filers | 8.73% | October 13, 2026 |
| Tenshi Healthcare Pte. Ltd.13D, may seek influence with 1 related filers | 6.4% | January 31, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 69 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 4,376,872 | +2,409,712 |
| Perceptive Advisors LLC | 3,139,216 | new |
| Marshall Wace, Llp | 1,987,578 | new |
| BlackRock, Inc. | 1,668,579 | +1,191,108 |
| Jane Street Group, LLC | 1,425,270 | new |
| Geode Capital Management, LLC | 1,245,868 | +642,262 |
| Susquehanna International Group, Llp | 968,190 | +834,106 |
| Vanguard Fiduciary Trust Co | 661,664 | +485,135 |
| Gilpin Wealth Management, LLC | 555,000 | -45,162 |
| State Street Corp | 539,802 | +376,700 |
| Cantor Fitzgerald, L. P. | 450,000 | new |
| Sanctuary Advisors, LLC | 344,529 | new |
| Raymond James Financial Inc | 332,051 | +305,000 |
| Group One Trading LLC | 246,428 | +132,727 |
| Northern Trust Corp | 237,561 | +170,171 |
| Simplex Trading, LLC | 205,013 | +72,347 |
| LPL Financial LLC | 184,942 | +151,315 |
| UBS Group AG | 152,215 | +19,146 |
| Deutsche Bank AG\ | 130,700 | new |
| Wealth Management Partners, LLC | 118,170 | new |
Insiders
7 insiders reported holding 25,592,178 shares in total, about $11.8M at the last price.
| Holder | Shares |
|---|---|
| Sukhtian Ghiath M.Director, 10% owner | 24,617,32024,617,320 held indirectly |
| Hilzinger Kurt JDirector | 423,655 |
| Sukhtian Faisal GhiathDirector | 220,972 |
| Jahr Robert CharlesChief Executive Officer, Director | 151,515 |
| Kenyon Lawrence AChief Financial Officer, Director | 106,956 |
| Haddadin Yezan MuntherDirector | 66,167 |
| Thurman Randy HDirector | 5,593 |
Questions about OTLK
What does Outlook Therapeutics, Inc. do?
Outlook Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as OTLK. Its shares trade on NASDAQ under the ticker OTLK.
What is Outlook Therapeutics, Inc.'s net worth?
Outlook Therapeutics, Inc. has a market value (market cap) of $111.8M at the latest share price, and shareholders' equity of -$10.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Outlook Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $61.1M.
When did Outlook Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 18, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 13, 2026.
When is Outlook Therapeutics, Inc.'s next earnings report?
Outlook Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare OTLK with
Follow OTLK
Get an email when Outlook Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Outlook Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.